Biostage Inc (BSTG) Given a $3.00 Price Target by Maxim Group Analysts
Biostage Inc (NASDAQ:BSTG) has been assigned a $3.00 price target by analysts at Maxim Group in a research report issued on Friday. The firm presently has a a “buy” rating on the stock. Maxim Group’s price target would suggest a potential upside of 219.15% from the company’s previous close.
Biostage (NASDAQ:BSTG) traded down 14.55% during mid-day trading on Friday, hitting $0.94. 376,226 shares of the company were exchanged. Biostage has a 12-month low of $0.53 and a 12-month high of $3.47. The stock’s market cap is $16.08 million. The company has a 50 day moving average of $1.05 and a 200 day moving average of $1.35.
Biostage (NASDAQ:BSTG) last posted its earnings results on Thursday, August 11th. The company reported ($0.17) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.21) by $0.04. On average, equities research analysts expect that Biostage will post ($0.86) earnings per share for the current fiscal year.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/07/biostage-inc-bstg-given-a-3-00-price-target-by-maxim-group-analysts-2.html
Biostage Company Profile
Biostage, Inc, formerly Harvard Apparatus Regenerative Technology, Inc, is a biotechnology company. The Company is engaged in developing bioengineered organ implants based on its Cellframe technology. Its Cellframe technology consists of a biocompatible scaffold that is seeded with the recipient’s own cells.
Receive News & Ratings for Biostage Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biostage Inc and related companies with MarketBeat.com's FREE daily email newsletter.